# US 2016/0237053 A1 · Tricyclic condensed heterocyclic compound, method for producing same, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237053 A1
- Document ID: US20160237053A1
- Status: Published application
- Kind: A1
- Application number: 15/066,603
- Filed: 2016-03-10
- Published: 2016-08-18
- Earliest claimed: 2009-03-30
- Assignees: Nippon Suisan Kaisha, Ltd.
- Applicants: Nippon Suisan Kaisha, Ltd.
- Inventors: Seizo SATO; Fumie IWATA; Shoichi YAMADA; Jiro TAKEO; Akihisa ABE; Hiroyuki KAWAHARA
- Web page: https://patentgrep.com/patent/US20160237053A1

## CPC

- C07D 307/93: condensed with a ring other than six-membered
- A61P 35/00: Antineoplastic agents
- C07D 307/77: ortho- or peri-condensed with carbocyclic rings or ring systems
- C12N 1/205: Bacterial isolates
- C12P 17/04: containing a five-membered hetero ring, e.g. griseofulvin {, vitamin C}
- C12R 2001/465: Streptomyces
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

A compound derived from the culture product of an actinomycete and having an antitumor activity is provided. Provided is a compound represented by any one of formulas (I), (II) and (III) or an optical isomer thereof or a pharmaceutically acceptable salt thereof which can be isolated from the culture fluid of an actinomycete which belongs to the genus Streptomyces, wherein R1, R2, R5 and R6 each independently represent a hydrogen atom, a methyl group, a hydroxymethyl group, a hydroxyl group, or a double bond by which R1 and R2 or R5 and R6 are bonded; R3, R4, R7 and R8 each independently represent a methyl group or a hydroxymethyl group; and R9 represents a hydrogen atom or a hydroxyl group.

## Claims

### Claim 1

A compound represented by any one of formulas (I), (II) and (III)
or an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein R1, R2, R5 and R6 each independently represent a hydrogen atom, a methyl group, a hydroxymethyl group, a hydroxyl group, or represent a double bond by which R1 and R2 or R5 and R6 are bonded; R3, R4, R7 and R8 each independently represent a methyl group or a hydroxymethyl group; and R9 represents a hydrogen atom or a hydroxyl group.

### Claim 2 (depends on 1)

The compound of claim 1 represented by any one of formulas (IV), (V) and (VI)
or an optical isomer thereof or a pharmaceutically acceptable salt thereof,
wherein R5 and R6 each independently represent a hydrogen atom, a methyl group, a hydroxymethyl group or a hydroxyl group; R3, R4, R7 and R8 each independently represent a methyl group or a hydroxymethyl group; and R9 represents a hydrogen atom or a hydroxyl group.

### Claim 3 (depends on 2)

The compound of claim 2 represented by formula (IV) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein each of R3, R4, R5, R6, R7 and R8 is a methyl group.

### Claim 4 (depends on 2)

The compound of claim 2 represented by formula (IV) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein R3 is a hydroxymethyl group, and each of R4, R5, R6, R7 and R8 is a methyl group.

### Claim 5 (depends on 2)

The compound of claim 2 represented by formula (IV) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein R4 is a hydroxymethyl group, and each of R3, R5, R6, R7 and R8 is a methyl group.

### Claim 6 (depends on 2)

The compound of claim 2 represented by formula (IV) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein R5 is a hydroxymethyl group, and each of R3, R4, R6, R7 and R8 is a methyl group.

### Claim 7 (depends on 2)

The compound of claim 2 represented by formula (IV) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein R6 is a hydroxymethyl group, and each of R3, R4, R5, R7 and R8 is a methyl group.

### Claim 8 (depends on 2)

The compound of claim 2 represented by formula (V) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, wherein R9 is a hydroxyl group, and each of R3, R5, R6, R7 and R8 is a methyl group.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising as an active ingredient the compound of claim 1 or an optical isomer thereof or a pharmaceutically acceptable salt thereof.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A process of producing the compound of claim 1, comprising:
culturing a microorganism capable of producing the compound of claim 1; and
isolating the compound of claim 1 from a product of the culturing,
wherein the microorganism capable of producing the compound of claim 1 is a microorganism which belongs to the genus Streptomyces.

### Claim 12 (depends on 1, 11)

The process of claim 11, wherein the microorganism capable of producing the compound of claim 1 is Streptomyces sp. NPS643 or a variant thereof.

### Claim 13 (depends on 1)

A process of producing a compound represented by formula (VII)
or an optical isomer thereof or a pharmaceutically acceptable salt thereof, comprising deriving a compound represented by formula (VII) or an optical isomer thereof or a pharmaceutically acceptable salt thereof from the compound of claims 1 or an optical isomer thereof or a pharmaceutically acceptable salt thereof used as a starting material, wherein R1, R4, R7, R10, R11 and R13 are each independently and arbitrarily selected from —CH2OH, —CH2O-lower alkyl, —CH2NH2, —CH2NH-lower alkyl, —CH2N(lower alkyl)2, —CH2-halogen, —COOH, —CO2-alkyl, —CONH2 and COH;
R2 and R3 are arbitrarily selected from combinations of (hereinafter, a halogen is referred to as “X”) (X,X), (H,X), (H2OH), (OH,H) and (H,NH2) (the substituents in the parentheses may be in any order) and an epoxy in which R2 and R3 are bonded to —O—;
R5 and R6, R8 and R9, and R12 and R14 are each independently and arbitrarily selected from combinations of (X,X), (H,X), (H2OH), (OH,X) and (H,NH2) (the substituents in the parentheses may be in any order) and an epoxy in which R5 and R6, R8 and R9, or R12 and R14 are bonded to —O—; and
bonds indicated with a to f are each independently a single bond or a double bond.
